Edition:
India

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

45.50USD
8:51pm IST
Change (% chg)

$0.30 (+0.66%)
Prev Close
$45.20
Open
$45.00
Day's High
$45.85
Day's Low
$44.45
Volume
51,388
Avg. Vol
237,084
52-wk High
$54.45
52-wk Low
$12.75

Chart for

About

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or... (more)

Overall

Beta: --
Market Cap(Mil.): $495.06
Shares Outstanding(Mil.): 30.56
Dividend: --
Yield (%): --

Financials

BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

08 May 2018

BRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration

* ATARA BIOTHERAPEUTICS EXPANDS T-CELL IMMUNOTHERAPY COLLABORATION TO ADVANCE NEXT-GENERATION CAR T TECHNOLOGIES IN ONCOLOGY, AUTOIMMUNE AND OTHER DISEASES Source text for Eikon: Further company coverage:

08 May 2018

BRIEF-Atara Biotherapeutics prices public offering of stock at $35 per share​

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

01 Mar 2018

BRIEF-Atara Biotherapeutics Files For Potential Mixed Shelf Offering

* ATARA BIOTHERAPEUTICS INC FILES FOR A POTENTIAL MIXED SHELF OFFERING; SIZE UNDISCLOSED - SEC FILING ‍​ Source text (http://bit.ly/2CKPbcB) Further company coverage:

28 Feb 2018

BRIEF-Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

28 Feb 2018

BRIEF-Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

27 Feb 2018

BRIEF-Atara Biotherapeutics Says CFO Intends To Retire In April 2018

* ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018

22 Feb 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

10 Jan 2018

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

05 Jan 2018

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

03 Jan 2018

Competitors

  Price Chg
Biogen Inc (BIIB.OQ) $294.84 +5.72
Bayer AG (BAYGn.DE) €96.82 -1.64
Bayer AG (BAYE.F) -- --
Teva Pharmaceutical Industries Limited (TEVA.TA) 8,610.00 -70.00
Merck KGaA (MRCG.DE) €82.34 -0.42
Sanofi SA (SASY.PA) €67.66 -0.59
Novartis AG (NOVN.S) CHF75.60 +0.10
Roche Holding Ltd. (ROG.S) CHF210.90 +0.90
Roche Holding Ltd. (RO.S) CHF216.60 +2.20

Earnings vs. Estimates